AbbVie terminates late-stage lung cancer trial


Aug 29 (Reuters) - AbbVie Inc ABBV.N on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.

An independent data monitoring committee recommended terminating the trial after an interim analysis of data from the trial testing its treatment, Rova-T, as first-line therapy, the company said.

AbbVie last year halted enrollment in a trial testing Rova-T as a second-line therapy in lung cancer.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

((; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.